EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways
NCT: NCT05773768 · COMPLETED
Brief Summary
In elderly atrial fibrillation (AF) patients, AF is usually a manifestation of risk factors and comorbidities not only limited to cardiovascular diseases. Especially in elderly often more than two comorbidities are present. The presence of comorbidities also affects outcomes in AF patients. Current healthcare systems are single-disease focused, which increases the risk of underdiagnosing, replicating diagnostic tests and adverse drug-drug interactions, placing a high burden on healthcare costs. Healthcare systems and hospitals are in need of new care pathways to address the complexity of multimorbid AF patients and to reduce costs. The EHRA-PATHS consortium set out to address this need for change in management for multimorbid, elderly AF patients in Europe through the development of new care pathways. The aim of this study is to evaluate the current management of risk factors and comorbidities, and subsequently implement the newly developed care pathways and evaluate if these pathways lead to better management of risk factors and comorbidities in multimorbid, elderly AF patients, compared to current standard care.
Frequently Asked Questions
What is EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways?
EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways is a clinical trial registered under NCT05773768. Current status: COMPLETED.
What is the status of NCT05773768?
The current status of NCT05773768 (EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways) is: COMPLETED.
When did EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways start?
EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways started on 2024-03-28.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.